Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

ClinicalTrials.gov ID: NCT01894672

Public ClinicalTrials.gov record NCT01894672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Trial of the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this phase II study is to find out if an investigational drug called LGX818 can stop the melanoma from growing.

Study identification

NCT ID
NCT01894672
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
7 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2013 (Type not available)
Primary completion
Mar 17, 2016 (Actual)
Completion
Mar 17, 2016 (Actual)
Last update posted
Jul 16, 2024

2013 – 2016

United States locations

U.S. sites
5
U.S. states
2
U.S. cities
5
Facility City State ZIP Site status
Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge New Jersey — —
Memorial Sloan Kettering Cancer Center at Commack Commack New York 11725 —
Memorial Sloan Kettering Cancer Center New York New York 10065 —
Memorial Sloan Kettering Cancer Center at Mercy Medical Center Rockville Centre New York 11570 —
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center Sleepy Hollow New York 10591 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01894672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 16, 2024 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01894672 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →